genocea
presents
data
neoantigen
vaccine
phase
trial
esmo
virtual
congress
responses
objective
responses
pr
cr
first
patients
suggests
added
benefit
inhibitor
therapy
patients
immune
responses
neoantigens
cambridge
globe
newswire
genocea
biosciences
nasdaq
gnca
biopharmaceutical
company
developing
neoantigen
immunotherapies
today
presents
additional
clinical
response
immunogenicity
data
first
five
patients
vaccinated
part
b
ongoing
phase
trial
european
society
medical
oncology
esmo
virtual
congress
esmo
presentation
poster
title
preliminary
results
pilot
trial
neoantigen
vaccine
containing
immunogenic
tumor
specific
neoantigens
combination
inhibitors
advanced
cancers
date
september
time
cest
edt
link
poster
https
meetings
registration
results
build
part
b
findings
shared
previously
evaluated
preliminary
immunogenicity
efficacy
combination
checkpoint
regimens
cpi
initial
cohort
five
patients
advanced
solid
tumors
five
patients
received
approximately
four
months
following
start
cpi
treatment
new
scans
ranging
days
confirm
previously
disclosed
findings
tumor
reduction
stable
outcomes
five
patients
including
three
changes
tumor
size
pr
cr
vaccination
likely
attributable
new
results
continue
suggest
vaccination
could
used
conjunction
therapies
augment
effects
addition
percent
patients
responses
elicited
vaccination
cases
evidence
epitope
spread
significant
adverse
side
effects
reported
mild
symptoms
associated
vaccine
adjuvant
response
curves
represent
promising
previously
unobserved
pattern
tumor
response
warrants
investigation
said
maura
gillison
professor
medicine
department
thoracic
head
neck
medical
oncology
md
anderson
cancer
center
important
continue
assessment
specific
contribution
clinical
effects
seen
date
look
forward
validating
results
broader
cohort
support
hypothesis
inclusion
cpi
regimens
may
lead
beneficial
outcomes
patients
solid
findings
show
recist
responses
maintained
least
three
months
three
five
patients
evaluated
underscore
potential
boost
cpi
regimens
hard
treat
patients
said
thomas
davis
chief
medical
officer
genocea
believe
path
forward
designing
better
immunotherapies
powered
atlas
results
build
confidence
indeed
targeting
relevant
tumor
antigens
inclusion
company
expects
share
additional
immunogenicity
clinical
data
remaining
part
b
patients
later
year
genocea
biosciences
genocea
mission
conquer
cancer
developing
personalized
cancer
immunotherapies
multiple
tumor
types
unique
platform
comprehensively
profiles
patient
cell
responses
potential
targets
antigens
tumor
atlas
enables
us
optimize
neoantigens
inclusion
immunotherapies
exclude
inhibitory
antigens
exert
immunosuppressive
effect
advancing
two
programs
neoantigen
vaccine
conducting
phase
clinical
trial
cell
therapy
using
cells
derived
peripheral
blood
expect
conduct
phase
clinical
trial
learn
please
visit
statements
press
release
includes
statements
including
statements
relating
within
meaning
private
securities
litigation
reform
act
statements
subject
risks
uncertainties
could
cause
actual
results
differ
materially
expressed
implied
statements
genocea
cautions
statements
subject
numerous
assumptions
risks
uncertainties
change
time
applicable
risks
uncertainties
include
identified
heading
risk
factors
included
genocea
annual
report
form
year
ended
december
subsequent
sec
filings
statements
speak
date
press
release
genocea
assumes
duty
update
statements
except
may
required
law
